Tag: Lymphoma

Scientists at the University of Minnesota Masonic Cancer Center have received notification from the U.S. Food and Drug Administration (FDA) that they can proceed...

Lymphoma - with its main forms Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) - is the most common blood cancer which occurs when cells...

Based on positive data from the Phase III AETHERA trial (SGN35-005; NCT01100502) of brentuximab vedotin (Adcetris®; Seattle Genetics, Inc/Takeda Oncology) as consolidation therapy immediately following...

esults from an interim phase I clinical trial presented at the 50th Annual Meeting of the American Association of Clinical Oncology (ASCO), being held May 30 - June 3, 2014 in Chicago, Ill, shows that SGN-CD19A (Seattle Genetics, Inc, Bothell, WA 98021, USA), an antibody-drug conjugate or ADC in development for the treatment of B-cell malignancies, offers encouraging anti-tumore activity in patients with Non-Hodgkin Lymphoma (NHL).[1]

Data presented at the 2014 Annual Bone Marrow Transplant (BMT) Tandem Meetings organized by The American Society for Blood and Marrow Transplantation and the Center for International Blood & Marrow Transplant Research being held in Grapevine (Dallas), Texas, February 26 - March 2, 2014, highlights the benefits of brentuximab vedotin (Adcetris®; Seattle Genetics) in various treatment schedules for hard to treat cancers.

Phase I interim data from a clinical trial with SGN-CD19A being developed for the treatment of B-cell malignancies, including acute lymphoblastic leukemia or ALL -- shows...

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38% of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in...

Results of a pivotal clinical trial with of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30 shows that the trial drug...